Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments. Many patients are treated with a combination of medications targeting different disease pathways, but some continue to have an inadequate response.
Riociguat is a medication that acts on the nitric oxide pathway and may be beneficial in patients who do not respond well to phosphodiesterase-5 inhibitors. In routine clinical practice, some patients receiving triple therapy switch from a phosphodiesterase-5 inhibitor to riociguat.
The REAPPRAISED study evaluates outcomes in patients with pulmonary arterial hypertension who switched to riociguat while receiving triple therapy. This observational study uses data from routine clinical care and does not involve any experimental treatment. The results may help improve understanding of the effectiveness and safety of this treatment strategy in real-world practice.
Adults aged 18 years or older.
Confirmed diagnosis of pulmonary arterial hypertension (Group 1).
Treatment with triple therapy including an endothelin receptor antagonist, a prostacyclin pathway agent, and a phosphodiesterase-5 inhibitor for at least 12 weeks.
Switch from a phosphodiesterase-5 inhibitor to riociguat as part of routine clinical care.
Concomitant use of phosphodiesterase-5 inhibitors and riociguat.
Inability to confirm vital status or hospitalization outcomes within 6 months.
Participation in an interventional clinical trial that mandated the treatment switch.
Caio Júlio César dos Santos Fernandes
Lead sponsor
University of Sao Paulo General Hospital
Sponsor institution